# NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices

Study · id `cardio:ct-nct07806149` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07806149](<https://clinicaltrials.gov/study/NCT07806149>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07806149

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT07806149. Non-randomized; no masking; primary purpose treatment. Start 2026-11-23 (anticipated); primary completion 2029-03-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT07806149, source copy `cardio:ctgov-nct07806149-2026-11-18`, retrieved 2026-11-18)
- Planned start: 2026-11-23 (anticipated) (ClinicalTrials.gov record NCT07806149, source copy `cardio:ctgov-nct07806149-2026-11-18`, retrieved 2026-11-18)
- Primary completion: 2029-03-01 (anticipated) (ClinicalTrials.gov record NCT07806149, source copy `cardio:ctgov-nct07806149-2026-11-18`, retrieved 2026-11-18)
- Completion: 2030-03-01 (anticipated) (ClinicalTrials.gov record NCT07806149, source copy `cardio:ctgov-nct07806149-2026-11-18`, retrieved 2026-11-18)
- Countries: United States (ClinicalTrials.gov record NCT07806149, source copy `cardio:ctgov-nct07806149-2026-11-18`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07806149-2026-11-18`, retrieved 2026-11-18)

## The registry's words

- Brief title: NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Multi-Center Prospective Study Using Improvised Off-Label Devices
- Condition: Hypertrophic Cardiomyopathy
- Condition: Left Ventricular Outflow Obstruction
- Condition: Systolic Anterior Motion
- Intervention (Device): SESAME Procedure
- Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI)
- Lead sponsor class: NIH

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

## Provenance

Content hash: d87ca6c815119aec84d4cf6b04fef94bf712e272d9ad24d78a1fe0dd51c79542
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
